Back to Search Start Over

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Authors :
Feldman, Andrew L.
Dasari, Surendra
Rimsza, Lisa M.
Scott, David W.
Oishi, Naoki
Amador, Catalina
Campo, Elias
Chan, Wing C.
Cook, James R.
Delabie, Jan
Farinha, Pedro
Fu, Kai
Greiner, Timothy C.
Inghirami, Giorgio
Iqbal, Javeed
Jaffe, Elaine S.
Ondrejka, Sarah L.
Ott, German
Pittaluga, Stefania
Raess, Phil
Rosenwald, Andreas
Savage, Kerry J.
Slack, Graham
Slager, Susan L.
Song, Joo Y.
Staudt, Louis M.
Wright, George
Wang, Hao-Wei
Zeng, Yu
Yoshino, Tadashi
Wu, Xiaojun
Wilcox, Ryan A.
Wang, Xueju
Satou, Akira
Perry, Anamarija M.
Miranda, Roberto
Medeiros, L. Jeffrey
Maurer, Matthew J.
Mou, Eric
Ko, Young Hyeh
Karube, Kennosuke
Kahl, Brad S.
Jiang, Liuyan
Jaye, David L
de Leval, Laurence
Chen, Weina
Chapman-Fredricks, Jennifer R.
Cerhan, James R.
Barrionuevo, Carlos
Ansell, Stephen M
Aljudi, Ahmed
Source :
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p847-847, 1p
Publication Year :
2023

Abstract

Background:Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell lymphomas that share pathologic features but differ in clinical presentation, outcome, and molecular features. The World Health Organization (WHO) and International Consensus Classification (ICC) classify ALCLs by presence or absence of ALKrearrangements (R) and clinical presentation (systemic, cutaneous [c], or breast implant-associated [BIA]). ICC, but not WHO, recognizes DUSP22-R as defining a new genetic subtype of ALK- ALCL. The classifications otherwise do not reflect additional molecular heterogeneity in genetics (e.g., TP63-R) or therapeutic vulnerabilities (e.g., JAK-STAT3 pathway activation).

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
142
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs64589319
Full Text :
https://doi.org/10.1182/blood-2023-186969